EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Prostate-specific antigen density as the best predictor of low- to intermediate-risk prostate cancer: a cohort study

Dae Hyoung Park, Ji Hyeong Yu

Translational Cancer Research · 2023-03 · 12 (3) · 502-514

DOI: 10.21037/tcr-22-1855 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Translational Cancer Research, 2023-03. Verfasst von Dae Hyoung Park und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, INJE University Sanggye Paik Hospital, Seoul, Republic of Korea. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evaluation of prostate cancer (PCa) when serum prostate-specific antigen (PSA) level is vaguely elevated is complicated. This is because serum PSA levels only reflect the number of prostate epithelial cells. We aimed to compare PSA and various prostate volume-related factors to determine which one can best predict PCa in patients with a PSA level of 2.5-20 ng/mL.

Methods

Patients who underwent transrectal ultrasound (TRUS)-guided prostate biopsy at the Inje University Sanggye Paik Hospital between January 2018 and July 2021 and who had a PSA level of 2.5-20 ng/mL were retrospectively identified (n=275). Among them, based on biopsy results, patients were divided into cancer group and non-cancer groups, and age, PSA, total prostate volume (TPV), peripheral zone volume (PZV), peripheral zone PSA density (PZ-PSAD), transitional zone-PSAD (TZ-PSAD), and PSAD were compared and analyzed using receiver operating characteristic (ROC) and univariate analyses.

Results

The areas under ROC curves (AUCs) for age, total PSA, TPV, PZV, PZ-PSAD, TZ-PSAD, and PSAD for predicting PCa in patients with a PSA level of 2.5-20.0 ng/mL were 0.678, 0.680, 0.671, 0.639, 0.731, 0.736, and 0.764, respectively. In univariate and multivariate analysis, all categorical variables were divided based on the cut-off value and used to predict PCa. Those with a PSAD of ≥0.218 ng/mL2 were found to be at an increased risk of PCa than those with a PSAD of

Schlagwörter

Stichwörter der Autor:innen

Prostate-specific antigen densitydigital rectal examination (DRE)lower urinary tract symptoms (LUTS)prostate cancer

Autor:innen und Institutionen

  • Department of Urology, INJE University Sanggye Paik Hospital, Seoul, Republic of Korea.

Zitieren

APA

Park, D. H., & Yu, J. H. (2023). Prostate-specific antigen density as the best predictor of low- to intermediate-risk prostate cancer: a cohort study. Translational Cancer Research, 12(3), 502-514. https://doi.org/10.21037/tcr-22-1855

Vancouver

Park DH, Yu JH. Prostate-specific antigen density as the best predictor of low- to intermediate-risk prostate cancer: a cohort study. Translational Cancer Research. 2023;12(3):502-514. doi:10.21037/tcr-22-1855

BibTeX
@article{Park2023,
  author = {Park, Dae Hyoung and Yu, Ji Hyeong},
  title = {Prostate-specific antigen density as the best predictor of low- to intermediate-risk prostate cancer: a cohort study},
  journal = {Translational Cancer Research},
  year = {2023},
  volume = {12},
  number = {3},
  pages = {502--514},
  doi = {10.21037/tcr-22-1855}
}
Kostenlos starten →